Directorate Change
CelLBxHealth plc has announced significant board changes, appointing Peter Collins as Chief Executive Officer and Klaas de Boer, Kim Oreskovic, and Benjamin Hart as Non-Executive Directors, effective immediately, to enhance strategic capabilities and drive shareholder value. Concurrently, Joseph Eid will step down as a Non-Executive Director on January 31, 2026. These appointments follow a previous announcement and are intended to leverage the new directors' extensive expertise in life sciences to support the company's focus on circulating tumour cell intelligence for research, drug development, and clinical oncology.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect:
- Peter Collins as Chief Executive Officer
- Klaas de Boer as Non-Executive Director
- Kim Oreskovic as Non-Executive Director
- Benjamin Hart as Non-Executive Director
The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.
Separately Non-Executive Director, Joseph Eid will step down from the board, effective 31 January 2026.
Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and the non-executives to the board. Their extensive expertise, combined with additional life sciences experience will significantly enhance the board's capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future."
AIM Rules Schedule 2 (g) information
The directorships and partnerships currently held by Peter Michael Collins, aged 67, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Saga Diagnostics UK Limited SAGA Diagnostics AB Collins Biotech Consulting SRL
The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
| Tsjukemar Ltd General Fusion Inc Xeros Technology Group plc SmartKem Inc Smartkem Ltd Fashion for Good BV | Entrepreneurs Fund Management LLP Entrepreneurs Fund Management Services Ltd veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH) Stichting Administratiekantoor Bellevue |
The directorships and partnerships currently held by Benjamin Jacob Hart, aged 38, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Applied Technology Partners LLC
The directorships and partnerships currently held by Kimberley Anne Oreskovic, aged 60, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Innoviance Investments B.V. Innoviance Consulting B.V.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.